As part of the new collaboration, Sheba and Biomica will engage in joint microbiome clinical research to develop better treatments for inflammatory bowel disease (IBD)
Sheba has teamed up with Biomica, an emerging biopharmaceutical company specializing in innovative microbiome-based therapeutics, to develop new treatments for patients who suffer from inflammatory bowel disease (IBD). IBD encompasses ulcerative colitis, Crohn’s disease, and other long-term conditions that involve gut inflammation.
By conducting deep sequencing and high-resolution analysis of microbiome samples obtained from IBD patients, Sheba and Biomica’s research will expand medicine’s understanding of IBD patients’ microbiomes, eventually leading to the development of new treatments that significantly improve quality of life.
In November 2021, Biomica reported positive pre-clinical results in its IBD program, following the evaluation of a live bacterial product developed to reduce intestinal tissue damage resulting from inflammation.
Commenting on the new collaboration, Dr. Yael Heberman, Head of the Microbiome Service at Sheba’s Pediatric Gastroenterology Department, stated: “I am very much looking forward to working with Biomica, a pioneer in the field of IBD and a developer of novel treatments based on the human microbiome. I believe our collaboration has great potential, and hope it will lead to improved outcomes for those suffering from IBD.”
